More Than 40 American Oncology Network Clinics Across 18 States and Washington, D.C., Now Offering Bispecific T-cell Engager Therapies to Patients

AON community oncology practices across the nation offering groundbreaking immunotherapy to expand treatment options for hard-to-treat cancers AON's implementation of BiTE therapies ensures patients across its national network can benefit from these innovations without the need to travel to academic medical centers or major research institutions. How Bispecific Therapies Work: Dual Targeting: Bispecific antibodies are engineered to recognize two targets—typically a cancer cell marker and a T cell receptor. ...